Aberrant DNA methylation in t(8;21) acute myeloid leukemia
-
Published:2022-08-08
Issue:4
Volume:3
Page:209-216
-
ISSN:2524-7662
-
Container-title:Genome Instability & Disease
-
language:en
-
Short-container-title:GENOME INSTAB. DIS.
Author:
He Shujiao,Zhou Jingfeng,Yu Li
Abstract
AbstractAberrant DNA methylation is a hallmark of acute myeloid leukemia (AML). Various studies showed that t(8;21) AML presented a distinct DNA methylation profile and could be categorized into a separate cluster according to DNA methylation sequencing. Yet, there is still a lack of understanding regarding the causes and mechanisms of this phenomenon. Knowing how the DNA methylation is regulated in t(8;21) AML would enhance our understanding of leukemogenesis and may assist clinical decision-making regarding DNA methylation-targeted therapy. Herein, we summarized our current knowledge concerning DNA methylation regulation in t(8;21) AML and discussed their potential clinical significance in this article.
Funder
Innovative Research Group Project of the National Natural Science Foundation of China National Natural Science Foundation of China Shenzhen Science and Technology Innovation Program Shenzhen Key Laboratory Fund Sanming Project of Medicine in Shenzhen
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Bayani, J., Selvarajah, S., Maire, G., Vukovic, B., Al-Romaih, K., Zielenska, M., & Squire, J. A. (2007). Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Seminars in Cancer Biology, 17, 5–18. 2. Breig, O., Bras, S., Martinez Soria, N., Osman, D., Heidenreich, O., Haenlin, M., & Waltzer, L. (2014). Pontin is a critical regulator for AML1-ETO-induced leukemia. Leukemia, 28, 1271–1279. 3. Cancer Genome Atlas Research, N, Ley, T. J., Miller, C., Ding, L., Raphael, B. J., Mungall, A. J., Robertson, A., Hoadley, K., Triche, T. J., Laird, P. W., et al. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine, 368, 2059–2074. 4. Christen, F., Hoyer, K., Yoshida, K., Hou, H. A., Waldhueter, N., Heuser, M., Hills, R. K., Chan, W., Hablesreiter, R., Blau, O., et al. (2019). Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): An international study on 331 patients. Blood, 133, 1140–1151. 5. Chung, W., Kelly, A. D., Kropf, P., Fung, H., Jelinek, J., Su, X. Y., Roboz, G. J., Kantarjian, H. M., Azab, M., & Issa, J. J. (2019). Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clinical Epigenetics, 11, 106.
|
|